drug
(sacubitril + valsartan)
Marketedupdated 3mo agoby Novugen Pharma (Malaysia) Sdn Bhd
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 8, 2026
79 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (24)
- May 9, 2036method-of-use (U-3170)US 11058667
- May 9, 2036method-of-use (U-3170)US 11058667
- May 9, 2036method-of-use (U-3170)US 11058667
- Aug 22, 2033method-of-use (U-3084)US 11135192
- Aug 22, 2033method-of-use (U-3084)US 11135192
- Aug 22, 2033method-of-use (U-3084)US 11135192
- Aug 22, 2033method-of-use (U-3084)US 9517226
- Aug 22, 2033method-of-use (U-3084)US 9517226
- Aug 22, 2033method-of-use (U-3084)US 9517226
- Aug 22, 2033method-of-use (U-3084)US 9937143
- Aug 22, 2033method-of-use (U-3084)US 9937143
- Aug 22, 2033method-of-use (U-3084)US 9937143
- Nov 27, 2027patentUS 8877938*PED1.3y
- Nov 27, 2027patentUS 8877938*PED1.3y
- Nov 27, 2027patentUS 8877938*PED1.3y
- May 27, 2027compositionUS 8877938279d
- May 27, 2027compositionUS 8877938279d
- May 27, 2027compositionUS 8877938279d
- May 8, 2027patentUS 9388134*PED260d
- May 8, 2027patentUS 9388134*PED260d
- May 8, 2027patentUS 9388134*PED260d
- Nov 8, 2026method-of-use (U-1723)US 938813479d
- Nov 8, 2026method-of-use (U-1723)US 938813479d
- Nov 8, 2026method-of-use (U-1723)US 938813479d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1m ago
Found something off?
comments(0)
5-min edit window · permanent after that